- Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise - Total deal value of over EUR1 billion; including EUR142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net product sales in Europe - Obicetrapib is a next-generation oral, low-dose and once-daily CETP inhibitor for which promising safety and strong LDL-lowering efficacy has been observed in patients with